Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
The film tells the story of a 70-year-old woman from Kota, Rajasthan, whose persistent cough led to a diagnosis of advanced lung cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
